BR100 Decreased By (-0.15%)
BR30 Decreased By (-0.74%)
KSE100 Decreased By (-0.41%)
KSE30 Decreased By (-0.67%)
BECO 5.80 Decreased By ▼ -0.23 (-3.81%)
BML 58.03 Increased By ▲ 5.28 (10.01%)
BOP 33.85 Decreased By ▼ -0.40 (-1.17%)
CNERGY 8.15 Decreased By ▼ -0.01 (-0.12%)
DCL 11.77 Decreased By ▼ -0.57 (-4.62%)
FCCL 53.35 Decreased By ▼ -0.54 (-1%)
FCSC 5.40 Increased By ▲ 0.18 (3.45%)
FFL 17.89 Decreased By ▼ -0.14 (-0.78%)
FNEL 1.31 Increased By ▲ 0.01 (0.77%)
HUMNL 11.06 Increased By ▲ 0.06 (0.55%)
KEL 8.05 Decreased By ▼ -0.06 (-0.74%)
KOSM 5.45 Increased By ▲ 0.07 (1.3%)
MLCF 87.19 Decreased By ▼ -0.86 (-0.98%)
NBP 184.60 Decreased By ▼ -1.88 (-1.01%)
PACE 11.62 Increased By ▲ 0.90 (8.4%)
PAEL 40.31 Increased By ▲ 0.37 (0.93%)
PIAHCLA 26.10 Decreased By ▼ -0.07 (-0.27%)
PIBTL 17.09 Decreased By ▼ -0.23 (-1.33%)
PPL 228.40 Decreased By ▼ -4.38 (-1.88%)
PRL 34.59 Decreased By ▼ -0.36 (-1.03%)
PTC 67.35 Decreased By ▼ -0.21 (-0.31%)
SEARL 91.00 Increased By ▲ 0.07 (0.08%)
SSGC 26.90 Decreased By ▼ -0.27 (-0.99%)
TELE 8.53 Decreased By ▼ -0.04 (-0.47%)
THCCL 66.14 Increased By ▲ 6.01 (10%)
TPLP 9.29 Increased By ▲ 0.53 (6.05%)
TREET 24.59 Increased By ▲ 0.05 (0.2%)
TRG 71.69 Decreased By ▼ -0.06 (-0.08%)
WAVES 10.98 Increased By ▲ 1.00 (10.02%)
WTL 1.28 Increased By ▲ 0.02 (1.59%)
World

RDIF says 3.5mn Russians have had both Sputnik V vaccine shots

  • Moscow says its vaccination programme is a global leader.
  • Says most successful in Europe in absolute numbers.
  • Data shows Russia lags others proportionally.
Published March 15, 2021 Updated March 15, 2021 09:26pm
By

MOSCOW: Russia has vaccinated 3.5 million people with both shots of its Sputnik V vaccine against COVID-19, which puts it ahead of all countries in Europe in terms of the absolute number of people fully vaccinated, its RDIF sovereign wealth fund said on Monday.

Kirill Dmitriev, head of RDIF, which is marketing Russia's Sputnik V vaccine globally, said the figures put Russia in the top five countries along with China, the United States, India and Israel when it comes to fully vaccinating people.

Dmitriev was pushing back against criticism from some Western media that Russia's domestic vaccination programme has been slow to get off the ground and less successful proportionately than other countries despite RDIF's success at marketing Sputnik globally.

"This indicator is often incorrectly compared to a total number of shots administered, whereas Russia uses a more conservative method based on full vaccination with two components," Dmitriev said in a statement.

If measured proportionately, Russia is doing less well -- the number of Russians he said had received both shots equates to around 2.4% of Russia's 144 million population.

That is lower than an average of 3.8% across the European Union and the European Economic Area, EU data showed.

TWO DOSES

The United States has administered two doses to more than 37 million people, its data showed, or 11% of the population.

Some countries such as Britain have prioritised giving a first shot to as many people as possible over administering a second dose. About 36% of Britons - more than 24 million people - have had their first dose.

Russia began rolling out its public vaccination campaign in early December, before the EU on Dec. 26.

Dmitriev confirmed that the RDIF had already reached agreements with companies from Italy, Spain, France and Germany to launch production of Sputnik V.

EU diplomatic sources have told Reuters that behind the scenes, the bloc is turning to Moscow's Sputnik V shot as it tries to get its stuttering efforts to vaccinate its 450 million people back on track.

"Currently there are additional talks ongoing to boost production in the EU," said Dmitriev.

"This will allow us to start supplying Sputnik V to the European single market once approval is granted by the European Medicines Agency (EMA)."

The EMA has begun a rolling review of Sputnik V.

Dmitriev said Moscow was also ready to supply EU states that approved Sputnik at a national level, as it has done with Hungary.

Comments

Comments are closed for this article.